KAKerry Atkinson

Kerry Atkinson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kerry Atkinson has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Manufacture of Clinical Grade Human Placenta-Derived Multipotent Mesenchymal Stromal Cells

    by Nina Ilic, Gary Brooke, Patricia Murray, Sarah Barlow, Tony Rossetti, Rebecca Pelekanos, Sonia Hancock, Kerry Atkinson

    Clinical grade human mesenchymal stem cells (MSC) are manufactured and used in clinical trials for a range of regenerative and inflammatory diseases. Human MSC have now been derived from tissues other than bone marrow, such as placenta, as described in this laboratory protocol. It provides instructions for clinical grade MSC manufacturing according to the Code of Good Manufacturing Practice (cGMP) principles and according to policies and procedures of our internal Quality Management System (QMS), which is based on the International Organization for Standardization (ISO) standard requirements. Relevant organizational structure and QMS elements are presented.


  • Open Access

    Cellular Therapy for Repair of Cardiac Damage after Acute Myocardial Infarction

    by Matthew M. Cook, Katarina Kollar, Gary P. Brooke, Kerry Atkinson

    Cardiovascular diseases, particularly acute myocardial infarction, are the leading causes of death worldwide. Important advances have been made in the secondary treatment for cardiovascular diseases such as heart transplantation and medical and surgical therapies. Although these therapies alleviate symptoms, and may even improve survival, none can reverse the disease process and directly repair the lasting damage. Thus, the cure of cardiovascular diseases remains a major unmet medical need. Recently, cellular therapy has been proposed as a candidate treatment for this. Many stem and progenitor cell populations have each been suggested as a potential basis for such therapy. This review assesses some of the more notable exogenous adult cell candidates and provides insights into the mechanisms by which they may mediate improvement in cardiac function following acute myocardial infarction. Research into the cellular therapy field is of great importance for the further planning of clinical trials for cardiac cellular myoplasty.


  • Manufacturing of human placenta‐derived mesenchymal stem cells for clinical trials

    by Gary Brooke, Tony Rossetti, Rebecca Pelekanos, Nina Ilic, Patricia Murray, Sonia Hancock, Vicki Antonenas, Gillian Huang, David Gottlieb, Ken Bradstock, et al.

    Summary: Mesenchymal stem cells (MSC) are being used increasingly in clinical trials for a range of regenerative and inflammatory diseases. Bone marrow is the traditional source but is relatively inaccessible in large volume. MSC have now been derived from tissues other than bone marrow including placenta and adipose tissue. We have used placenta obtained after delivery as a source of MSC and have been unable to detect any marked differences from marrow‐derived MSC in terms of cell surface phenotype, chemokine receptor display, mesodermal differentiation capacity or immunosuppressive ability. This report described our manufacturing process for isolating and expanding placenta‐derived human MSC and their safe infusion into the first patient in a clinical trial program of human placenta‐derived MSC.